Genoray Co. Ltd (122310) - Total Assets
Based on the latest financial reports, Genoray Co. Ltd (122310) holds total assets worth ₩131.23 Billion KRW (≈ $88.93 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Genoray Co. Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Genoray Co. Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Genoray Co. Ltd's total assets have evolved over time, based on quarterly financial data. Explore 122310 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Genoray Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Genoray Co. Ltd's total assets of ₩131.23 Billion consist of 59.2% current assets and 40.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.5% |
| Accounts Receivable | ₩13.27 Billion | 10.1% |
| Inventory | ₩45.36 Billion | 34.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.35 Billion | 5.6% |
| Goodwill | ₩206.00 Million | 0.2% |
Asset Composition Trend (2015–2025)
This chart illustrates how Genoray Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 122310 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genoray Co. Ltd's current assets represent 59.2% of total assets in 2025, an increase from 58.3% in 2015.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2025, up from 9.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 23.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 34.6% of total assets.
Genoray Co. Ltd Competitors by Total Assets
Key competitors of Genoray Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Genoray Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.94 | 2.42 | 3.24 |
| Quick Ratio | 0.81 | 0.99 | 2.00 |
| Cash Ratio | 0.00 | 0.53 | 0.00 |
| Working Capital | ₩37.70 Billion | ₩43.36 Billion | ₩43.93 Billion |
Genoray Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Genoray Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.3% |
| Total Assets | ₩131.23 Billion |
| Market Capitalization | $28.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genoray Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Genoray Co. Ltd's assets grew by 6.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Genoray Co. Ltd (2015–2025)
The table below shows the annual total assets of Genoray Co. Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩131.23 Billion ≈ $88.93 Million |
+6.31% |
| 2024-12-31 | ₩123.44 Billion ≈ $83.66 Million |
-0.66% |
| 2023-12-31 | ₩124.27 Billion ≈ $84.22 Million |
+17.02% |
| 2022-12-31 | ₩106.20 Billion ≈ $71.97 Million |
+6.87% |
| 2021-12-31 | ₩99.37 Billion ≈ $67.34 Million |
+15.89% |
| 2020-12-31 | ₩85.74 Billion ≈ $58.11 Million |
+9.20% |
| 2019-12-31 | ₩78.52 Billion ≈ $53.21 Million |
+34.36% |
| 2018-12-31 | ₩58.44 Billion ≈ $39.60 Million |
+54.88% |
| 2017-12-31 | ₩37.73 Billion ≈ $25.57 Million |
+13.01% |
| 2016-12-31 | ₩33.39 Billion ≈ $22.63 Million |
+17.00% |
| 2015-12-31 | ₩28.54 Billion ≈ $19.34 Million |
-- |
About Genoray Co. Ltd
Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It provides C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services. The company also exports its products to approximately 80 countries worldwide. Genoray Co., Ltd. was founded … Read more